Panthera Joins Parexel’s Global Site Alliance Vaccine Network

Parexel has announced that Panthera Biopartners has become the first public or commercial clinical trial organization in the UK to join the Parexel Site Alliance Vaccine Network. This global network partners with top-performing clinical trial sites, fostering long-term collaborations to enhance efficiencies for patients, research sites, and biopharma clients.

Panthera was chosen due to its outstanding patient recruitment performance in numerous studies and its strong collaboration with Parexel. Over the past two years, Panthera has become the UK's leading recruiter and operator of commercial clinical trials, ranking as the top recruiter globally in four studies and the UK leader in six others. The company has also achieved "first patient in" milestones in nine studies, either globally or in the UK.

These achievements are critical for pharmaceutical companies and CROs when selecting clinical trial sites for patient recruitment.

Chris Dodd, Chief Commercial Officer of Panthera, expressed pride in being the first UK site selected for Parexel’s Site Alliance Vaccine Network. He emphasized the importance of Panthera’s efforts in meeting or exceeding patient recruitment goals and highlighted the value of partnering with Parexel to further expand clinical research opportunities in the UK.

Currently, fewer than 10% of physicians and patients engage in clinical research, with minority groups particularly underrepresented. Clinical trials tend to be concentrated in academic and investigator sites, limiting awareness and participation among patients and healthcare providers. Panthera, as a Site Management Organization (SMO), focuses solely on patient recruitment and trial operations. The company works closely with local GPs in the UK, leveraging targeted advertising and social media to ensure diverse communities have access to clinical trials and the latest treatments.